Virtu Financial LLC Invests $30,000 in Shattuck Labs, Inc. (NASDAQ:STTK)

Virtu Financial LLC bought a new stake in Shattuck Labs, Inc. (NASDAQ:STTK) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 24,446 shares of the company’s stock, valued at approximately $30,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Atom Investors LP acquired a new stake in Shattuck Labs during the 3rd quarter valued at approximately $35,000. Readystate Asset Management LP acquired a new position in Shattuck Labs during the third quarter valued at $39,000. Benjamin Edwards Inc. acquired a new position in Shattuck Labs during the third quarter valued at $61,000. MetLife Investment Management LLC grew its position in Shattuck Labs by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 24,596 shares of the company’s stock worth $86,000 after purchasing an additional 13,859 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in shares of Shattuck Labs by 63.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 27,533 shares of the company’s stock valued at $96,000 after buying an additional 10,667 shares during the last quarter. Institutional investors and hedge funds own 58.74% of the company’s stock.

Shattuck Labs Price Performance

Shares of STTK stock opened at $0.85 on Wednesday. Shattuck Labs, Inc. has a 1-year low of $0.85 and a 1-year high of $11.76. The company has a market cap of $40.38 million, a price-to-earnings ratio of -0.55 and a beta of 1.66. The stock has a 50 day simple moving average of $1.23 and a 200-day simple moving average of $1.42.

Shattuck Labs (NASDAQ:STTK) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.01. Shattuck Labs had a negative net margin of 1,156.46% and a negative return on equity of 61.92%. Analysts anticipate that Shattuck Labs, Inc. will post -1.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Leerink Partners started coverage on Shattuck Labs in a research note on Monday, March 17th. They issued an “outperform” rating and a $4.00 target price on the stock. HC Wainwright reaffirmed a “neutral” rating on shares of Shattuck Labs in a research note on Thursday, March 27th. Leerink Partnrs upgraded shares of Shattuck Labs to a “strong-buy” rating in a research note on Monday, March 17th. Finally, Needham & Company LLC restated a “hold” rating on shares of Shattuck Labs in a research report on Thursday, March 27th. Four equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Shattuck Labs presently has an average rating of “Moderate Buy” and an average price target of $7.50.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.